Dr. Edwin Moses is one of LifeScience ORG’s Ambassadors and most prominent serial life science entrepreneurs in Europe. As a CEO for a total of almost 20 years, he successfully built two businesses (Oxford Asymmetry International plc and Ablynx nv), led their IPOs on the LSE, EuroNext and NASDAQ and raised over €500M in equity and debt financing. He also ran the sales process for Oxford Asymmetry to Evotec for £316M and Ablynx to Sanofi for €3.9Bn respectively.

At Ablynx, Edwin ensured that the novel Nanobody technology platform was used to build a broad product pipeline, including Cablivi™ which was recently approved for use in both Europe and the USA. In addition, he helped secure pharmaceutical collaborations with a potential value of >€10Bn. Edwin has expertise in high value service provision to the pharmaceutical industry and in drug discovery and development, with more than 25 years of Board level experience in >20 companies.

He is currently Chairman of Achilles Therapeutics (UK), Avantium NV (Netherlands), LabGenius Ltd (UK) and a board member of Abliva AB (Sweden). Edwin has previously chaired Sensorion (France), Virion Biotherapeutics and Evox Therapeutics (both UK), as well as being an Operational Partner at Keensight Capital.